Walleye Capital LLC bought a new stake in shares of CinCor Pharma, Inc. (NASDAQ:CINC – Get Rating) in the first quarter, HoldingsChannel reports. The institutional investor bought 28,250 shares of the company’s stock, valued at approximately $496,000.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. UBS Group AG purchased a new stake in CinCor Pharma during the first quarter valued at approximately $38,000. California State Teachers Retirement System purchased a new stake in CinCor Pharma during the first quarter valued at approximately $87,000. JPMorgan Chase & Co. purchased a new stake in shares of CinCor Pharma in the first quarter worth $95,000. American International Group Inc. purchased a new stake in shares of CinCor Pharma in the first quarter worth $101,000. Finally, MetLife Investment Management LLC purchased a new stake in shares of CinCor Pharma in the first quarter worth $142,000.
Insider Buying and Selling at CinCor Pharma
In other CinCor Pharma news, major shareholder Sofinnova Venture Partners X, acquired 500,000 shares of the stock in a transaction on Thursday, August 11th. The stock was acquired at an average price of $30.00 per share, for a total transaction of $15,000,000.00. Following the completion of the transaction, the insider now directly owns 6,073,949 shares of the company’s stock, valued at $182,218,470. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, major shareholder 5Am Partners Vi, Llc bought 600,000 shares of CinCor Pharma stock in a transaction dated Monday, August 15th. The shares were acquired at an average price of $30.00 per share, with a total value of $18,000,000.00. Following the completion of the purchase, the insider now owns 3,953,990 shares in the company, valued at approximately $118,619,700. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Sofinnova Venture Partners X, bought 500,000 shares of CinCor Pharma stock in a transaction dated Thursday, August 11th. The stock was purchased at an average cost of $30.00 per share, for a total transaction of $15,000,000.00. Following the purchase, the insider now owns 6,073,949 shares of the company’s stock, valued at approximately $182,218,470. The disclosure for this purchase can be found here. Insiders acquired 1,606,000 shares of company stock worth $48,180,000 over the last 90 days.
Analyst Ratings Changes
CinCor Pharma Trading Up 3.2 %
CINC stock opened at $28.11 on Friday. CinCor Pharma, Inc. has a 52 week low of $13.00 and a 52 week high of $43.15. The company has a fifty day simple moving average of $29.41 and a two-hundred day simple moving average of $22.96.
CinCor Pharma (NASDAQ:CINC – Get Rating) last released its quarterly earnings data on Monday, August 8th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.06). On average, equities analysts predict that CinCor Pharma, Inc. will post -2.34 EPS for the current fiscal year.
CinCor Pharma Company Profile
CinCor Pharma, Inc, a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases.
- Get a free copy of the StockNews.com research report on CinCor Pharma (CINC)
- What Steelcase’s Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for CinCor Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CinCor Pharma and related companies with MarketBeat.com's FREE daily email newsletter.